NEW YORK (GenomeWeb News) – JPT Peptide Technologies and The Institute for Medical Immunology at the Charite in Berlin announced on Wednesday an agreement to develop serological peptide biomarkers for the differential diagnosis of chronic fatigue syndrome.

Under the terms of the deal, JPT will combine its high-content peptide microarray technology with the institute's expertise in diagnosing patients with chronic fatigue syndrome in order to discover biomarkers that can be developed into diagnostic tools.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.